Gilead Sciences, Inc. (GILD) Shares Sold by Polianta Ltd

Polianta Ltd trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,000 shares of the biopharmaceutical company’s stock after selling 900 shares during the quarter. Polianta Ltd’s holdings in Gilead Sciences were worth $1,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Gilead Sciences during the 2nd quarter worth about $132,000. Brand Asset Management Group Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth about $139,000. Aspen Investment Management Inc acquired a new stake in Gilead Sciences during the 1st quarter worth about $207,000. LFA Lugano Financial Advisors SA lifted its position in Gilead Sciences by 127.0% during the 3rd quarter. LFA Lugano Financial Advisors SA now owns 2,760 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 1,544 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in Gilead Sciences during the 2nd quarter worth about $206,000. Hedge funds and other institutional investors own 77.99% of the company’s stock.

Shares of Gilead Sciences stock traded down $0.45 on Monday, hitting $73.14. The company’s stock had a trading volume of 67,947 shares, compared to its average volume of 7,328,163. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The firm has a market cap of $100.09 billion, a PE ratio of 8.54, a P/E/G ratio of -3.92 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the previous year, the business earned $2.56 EPS. Gilead Sciences’s revenue for the quarter was down 20.9% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 6.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 27th. Investors of record on Friday, September 14th were paid a $0.57 dividend. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.12%. Gilead Sciences’s dividend payout ratio is presently 26.64%.

In related news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total value of $3,892,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 150,000 shares of company stock valued at $11,502,500. 1.16% of the stock is owned by company insiders.

GILD has been the subject of a number of research reports. BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 20th. ValuEngine cut Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, June 27th. Raymond James started coverage on Gilead Sciences in a report on Thursday, June 28th. They issued a “strong-buy” rating and a $93.00 price objective for the company. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a report on Wednesday, July 18th. Finally, Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a report on Thursday, July 26th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $88.24.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply